Global Short Bowel Syndrome Market, 2017 to 2025: Growing Prescriptions of Gattex and Revestive in U.S. and Europe Respectively is Boosting the Growth of the Market

Global Short Bowel Syndrome Market, 2017 to 2025: Growing Prescriptions of Gattex and Revestive in U.S. and Europe Respectively is Boosting the Growth of the Market

Dublin, Feb. 07, 2018 (GLOBE NEWSWIRE) -- The

GlobeNewswire News Room (www.globenewswire.com)

"The market was valued at US$ 315.1 Mn in 2016, and is expected to reach US$ 2,901.0 Mn by 2025, expanding at a CAGR of 27.5% from 2017 to 2025."

2019-07-24
BAQSIMI (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA
https://investor.lilly.com/news-releases/news-release-details/baqsimitm-glucagon-nasal-powder-3-mg-first-and-only-nasally

2018-01-30
Biotech Zealand Pharma bets on self-marketing over big pharma partnerships
https://www.reuters.com/article/zealand-strategy/biotech-zealand-pharma-bets-on-self-marketing-over-big-pharma-partnerships-idUSL8N1PK518
"Sales of Soliqua, which is a combination of insulin and a GLP-1, has been below both analysts and Sanofi's own expectations since the drug was launched in the United States a year ago, Sanofi said in its third-quarter results in November."

2019-05-17
U.S. FDA Approves GATTEX (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)
https://www.takeda.com/en-us/newsroom/news-releases/2019/u.s.-fda-approves-gattex-teduglutide-for-children-1-year-of-age-and-older-with-short-bowel-syndrome-sbs/

Gattex-salg 2019Q3YTD 46.9 JPYmia = 430 USDmio.

Hvis Zealand lykkes (godkendelsen og salg) med glepaglutid, saa kan selskabet sagtens vaere 20 milliarder kroner vaerd. Dasiglucagon tror jeg fortsat ikke paa. Dertil er baade alternativerne og nye laegemidler, der ikke forarsaager hypoglykaemi for gode.

Ikke så ringe endda